Unknown

Dataset Information

0

Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions.


ABSTRACT: With the progress of sequencing technologies, an ever-increasing number of variants of unknown functional and clinical significance (VUS) have been identified in both coding and non-coding regions of the main Breast Cancer (BC) predisposition genes. The aim of this study is to identify a mutational profile of coding and intron-exon junction regions of 12 moderate penetrance genes (ATM, BRIP1, CDH1, CHEK2, NBN, PALB2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53) in a cohort of 450 Italian patients with Hereditary Breast/Ovarian Cancer Syndrome, wild type for germline mutation in BRCA1/2 genes. The analysis was extended to 5'UTR and 3'UTR of all the genes listed above and to the BRCA1 and BRCA2 known regulatory regions in a subset of 120 patients. The screening was performed through NGS target resequencing on the Illumina platform MiSeq. 8.7% of the patients analyzed is carriers of class 5/4 coding variants in the ATM (3.6%), BRIP1 (1.6%), CHEK2 (1.8%), PALB2 (0.7%), RAD51C (0.4%), RAD51D (0.4%), and TP53 (0.2%) genes, while variants of uncertain pathological significance (VUSs)/class 3 were identified in 9.1% of the samples. In intron-exon junctions and in regulatory regions, variants were detected respectively in 5.1% and in 32.5% of the cases analyzed. The average age of disease onset of 44.4 in non-coding variant carriers is absolutely similar to the average age of disease onset in coding variant carriers for each proband's group with the same cancer type. Furthermore, there is not a statistically significant difference in the proportion of cases with a tumor onset under age of 40 between the two groups, but the presence of multiple non-coding variants in the same patient may affect the aggressiveness of the tumor and it is worth underlining that 25% of patients with an aggressive tumor are carriers of a PTEN 3'UTR-variant. This data provides initial information on how important it might be to extend mutational screening to the regulatory regions in clinical practice.

SUBMITTER: Guglielmi C 

PROVIDER: S-EPMC8305371 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications


With the progress of sequencing technologies, an ever-increasing number of variants of unknown functional and clinical significance (VUS) have been identified in both coding and non-coding regions of the main Breast Cancer (BC) predisposition genes. The aim of this study is to identify a mutational profile of coding and intron-exon junction regions of 12 moderate penetrance genes (<i>ATM</i>, <i>BRIP1</i>, <i>CDH1</i>, <i>CHEK2</i>, <i>NBN</i>, <i>PALB2</i>, <i>PTEN</i>, <i>RAD50</i>, <i>RAD51C<  ...[more]

Similar Datasets

| S-EPMC4392522 | biostudies-literature
| S-EPMC9647983 | biostudies-literature
| S-EPMC5049788 | biostudies-literature
| S-EPMC10905677 | biostudies-literature
| S-EPMC5650145 | biostudies-literature
| S-EPMC8754628 | biostudies-literature
| S-EPMC4070550 | biostudies-literature
| S-EPMC5369655 | biostudies-literature
| S-EPMC7226062 | biostudies-literature
| S-EPMC7650720 | biostudies-literature